AG
FHTX icon

Artal Group’s Foghorn Therapeutics FHTX Stock Holding History

Artal Group’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-720,720
Closed -$4.14M – 36
2024
Q2 		$4.14M Hold
720,720
– – 0.11% 61
2024
Q1 		$4.84M Hold
720,720
– – 0.12% 65
2023
Q4 		$4.65M Sell
720,720
-1,000,000
-58% -$4.31M 0.15% 53
2023
Q3 		$8.6M Hold
1,720,720
– – 0.37% 44
2023
Q2 		$12.1M Hold
1,720,720
– – 0.38% 40
2023
Q1 		$10.7M Hold
1,720,720
– – 0.63% 40
2022
Q4 		$11M Hold
1,720,720
– – 0.61% 40
2022
Q3 		$14.8M Hold
1,720,720
– – 0.63% 36
2022
Q2 		$23.4M Hold
1,720,720
– – 1.25% 20
2022
Q1 		$26.2M Hold
1,720,720
– – 1.1% 21
2021
Q4 		$39.4M Hold
1,720,720
– – 1.07% 27
2021
Q3 		$24M Hold
1,720,720
– – 0.54% 45
2021
Q2 		$18.4M Hold
1,720,720
– – 0.37% 58
2021
Q1 		$22.7M Hold
1,720,720
– – 0.4% 57
2020
Q4 		$34.9M Buy
+1,720,720
New +$33M 0.75% 35

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group's FHTX Position: Q3 2024 in Review

Artal Group sold out of Foghorn Therapeutics (FHTX) in Q3 2024, closing a stake of 720,720 shares — an estimated $4.14M sold.

Artal Group first reported a position in FHTX in Q4 2020 and held it in 15 quarters. The position peaked at $39.4M in Q4 2021. 79 funds tracked by Wall St. Rank hold FHTX as of Q3 2024.

  • Artal Group reported no remaining Foghorn Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 720,720 Foghorn Therapeutics shares in Q3 2024, an estimated $4.14M.
  • Artal Group first reported a position in Foghorn Therapeutics in Q4 2020 and held it in 15 quarters.
  • Artal Group's Foghorn Therapeutics position peaked at $39.4M in Q4 2021.
  • 79 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.